What's new on the horizon for rheumatoid arthritis management

IF 4.8 2区医学 Q1 RHEUMATOLOGY Best Practice & Research in Clinical Rheumatology Pub Date : 2025-03-01 Epub Date: 2025-02-11 DOI:10.1016/j.berh.2025.102038

Karmtej S. Cheema , Andrew Bit Mansour , Siba P. Raychaudhuri

引用次数: 0

Abstract

Rheumatoid arthritis (RA) is a chronic multisystem common autoimmune disease. Joints and the whole musculoskeletal system bear the brunt of the disease. Proper adequate treatment at the early stage is the foremost necessity to protect the patients from long term disabilities and reduce patient systemic morbidities including atherosclerosis and coronary artery disease. New biologic and non-biologic antirheumatic drugs in the last two decades have brought new dimensions for treat to target strategy and array of novel therapies for RA are in the horizon. Here in this systematic review our objective is to provide an overview of current developments and potentially available therapeutic options for RA. Novel immune-based therapies has the potential to change the treatment for RA. We have discussed in detail about the new drugs for RA in the horizon and provided analyses of the future drugs in pipeline for the management of RA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

类风湿关节炎治疗的新进展是什么？

类风湿性关节炎（RA）是一种慢性多系统常见自身免疫性疾病。关节和整个肌肉骨骼系统首当其冲。在早期阶段进行适当、充分的治疗是保护患者免于长期残疾和减少患者全身性疾病（包括动脉粥样硬化和冠状动脉疾病）的首要条件。过去二十年中，新的生物和非生物抗风湿药物为靶向治疗策略带来了新的发展空间，一系列治疗RA的新型疗法即将问世。在这篇系统性综述中，我们的目标是概述当前的发展情况和可能的 RA 治疗方案。基于免疫的新型疗法有可能改变 RA 的治疗方法。我们详细讨论了地平线上治疗RA的新药，并对未来用于治疗RA的在研药物进行了分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Best Practice & Research in Clinical Rheumatology 医学-风湿病学

CiteScore

9.40

自引率

0.00%

发文量

审稿时长

27 days

期刊介绍： Evidence-based updates of best clinical practice across the spectrum of musculoskeletal conditions. Best Practice & Research: Clinical Rheumatology keeps the clinician or trainee informed of the latest developments and current recommended practice in the rapidly advancing fields of musculoskeletal conditions and science. The series provides a continuous update of current clinical practice. It is a topical serial publication that covers the spectrum of musculoskeletal conditions in a 4-year cycle. Each topic-based issue contains around 200 pages of practical, evidence-based review articles, which integrate the results from the latest original research with current clinical practice and thinking to provide a continuous update. Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. The review articles seek to address the clinical issues of diagnosis, treatment and patient management. Management is described in practical terms so that it can be applied to the individual patient. The serial is aimed at the physician in both practice and training.

期刊最新文献

T-cell engagers in rheumatology. CAR-T cell therapy for ANCA-associated vasculitis: Rationale, current evidence, and future directions. CAR T-cell therapy "Living drugs" in systemic lupus erythematosus. State of the art and novel treatments in psoriatic arthritis. Renal involvement in systemic sclerosis.